Navigation Links
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:3/28/2008

et conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including claims and concerns about product safety and efficacy; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations. Also, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
2. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
7. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
8. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/15/2014)... Dec. 15, 2014 Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology,  today ... collaborators of its exVive3D TM Human Liver ... in full commercial release on November 18, has ... in several awards for innovation. Most ...
(Date:12/13/2014)... 2014 /CNW/ - MaRS and Virgin Unite Canada, the non-profit ... joined forces to support Canadian entrepreneurs tackling social and environmental ... was at the MaRS Centre to announce the new partnership, ... fund. This fund has $1 million in seed capital provided ... -based Mindset Social Innovation Foundation, founded by Alison Lawton ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... CAMBRIDGE, Massachusetts, February 20, Shire plc (LSE: SHP, ... company, announced today that it has officially,opened a ... Soh Fujiwara as,Managing Director for Japanese operations. , ... Shinkujuku Ward, Tokyo, will serve as the base ...
... Sciences presented important new results on the continued ... HIV-1 at the 16th Conference on Retroviruses and ... focused on the results of IND-directed development of ... formulation of IQP-0528 as a topical microbicide to ...
... Inc. (Nasdaq: ITMN ) announced today that it ... Thursday, February 26, 2009 at 4:00 p.m. Eastern time. ... InterMune at 4:30 p.m. Eastern time that same day. , ... (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access ...
Cached Biology Technology:Shire Announces Opening of Office in Japan 2Shire Announces Opening of Office in Japan 3ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 2ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 3InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26 2
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... at Yale provided a glimpse of the ancient mechanism ... between gene processing in humans and the most primitive ... crucial self-splicing region of RNA. Genes of higher ... molecules. But, after transcription from the DNA, these RNAs ...
... at UT Southwestern Medical Center have developed a simple ... pull out a handful that might treat cancer and ... one screen of more than 300,000 such molecules, called ... candidates that mimicked an antibody already on the market ...
... Research present in a forthcoming issue of the International ... dental implants with a synthetic bone material prior to ... successfully into the jaw, leading to smiles all round. ... dental and medical implants. However pure titanium has a ...
Cached Biology News:Yale scientists visualize the machinery of mRNA splicing 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 2Synthetic molecules may be less expensive alternative to therapeutic antibodies, researchers find 3Crowning glory 2
... Software reads and processes raw ... microarray data for analysis. ... one 1-year license for Feature ... ,one CD-ROM containing Feature Extraction ...
... CHEMICONs ELF 97 Cytological Labeling Kit provides ... the detection of cellular targets, including cell-surface ... Cytological Labeling Kit contains the patented ELF ... fluorescent yellow-green precipitate at the site of ...
... Many differences exist between the various commercial ... glass slide used, the length and GC ... and the manufacturing protocol employed all influence ... analysis. With all the different variables ...
... SYBR Safe DNA Gel Stain combo offers these benefits: ... these same products separately ... Eliminates risks to yourself, ... RNA fragments from 100 bp to >30 kb. UltraPure ...
Biology Products: